药物性肝损伤生物标志物研究进展  

Progress in the biomarker discovery for drug-induced liver injury

作　　者：贺蕾艳 郭瑶雪[1,2,3] 李春[1,2,3] 邓晔[1,2,3] 张啟智[1] 彭文兴[1,2] 

机构地区：[1]中南大学湘雅二医院药学部,湖南长沙410011 [2]中南大学临床药学研究所,湖南长沙410011 [3]中南大学药学院,湖南长沙410013

出　　处：《药学学报》2015年第8期959-965,共7页Acta Pharmaceutica Sinica

摘　　要：药物性肝损伤是导致上市药物撤市和药物临床试验失败最主要的原因之一。药物性肝损伤体征的非特异性和肝损伤致病机制的复杂性等阻碍了对药物性肝损伤的及时诊断和有效治疗。传统的检测指标如血清转氨酶、总胆红素和总胆汁酸等在对药物性肝损伤的早期诊断等方面具有一定的限制。近年来多项研究试图从血液、尿液中发现更为理想的生物标志物,提高对药物性肝损伤检测与诊断的特异性与灵敏性。本文就近年来发现的新型潜在生物标志物予以综述。The leading cause of drug withdrawal from market and clinical trials failure is drug-induced liver injury （DILI）. Varying clinical, histological and laboratory features of DILI, as well as undefined underlying mechanisms, hinder patients to be diagnosed in the early-stage of the disease and receive effective treatments. Conventional indicators, like serum transaminases and bilirubin, have inevitable limitations referring to sensitive prediction and specific detection of DILL In order to reduce the occurrence of DILI, researchers have attempted to discover potential biomarkers with higher specificity and sensitivity from blood and urine in recent years. This article aims to review recent advances in biomarkers of DILI.

关 键 词：药物性肝损伤 肝毒性 生物标志 

分 类 号：R963[医药卫生—微生物与生化药学]